U.S. Congressional Investigation Of Tainted Heparin Could Highlight Need For Import Safety Legislation - Or Not
This article was originally published in PharmAsia News
Executive Summary
A U.S. House of Representatives Energy and Commerce Committee investigation into who caused contamination of heparin supplies in 2007 and 2008, how it was done, and U.S. FDA's handling of the crisis, could revive interest in legislation designed to strengthen FDA's oversight of drugs and other medical products entering the U.S. from overseas